Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are conducting an international, multicenter observational study to understand acute kidney injury requiring renal replacement therapy AKI-RRT in Latin American countries. The study focuses on the epidemiology, outcomes, and care processes for patients with AKI-RRT, comparing variations across different countries and examining factors such as demographics, clinical profiles, and socioeconomic status that may influence patient outcomes. The aim is to establish a comprehensive database to support clinical research and improve understanding of AKI-RRT in this region. The study observes critically ill adult patients admitted to intensive care units ICUs who are undergoing any form of renal replacement therapy. It collects detailed clinical, laboratory, treatment, and outcome data without assigning treatments, as it is observational. Patients are followed from enrollment through hospital discharge or up to 90 days, including ICU stay and 90-day post-ICU follow-up to track mortality, renal recovery, and complications related to renal replacement therapy. Participants involvement includes monitoring during ICU and hospital stays with data collected on mortality rates, length of stay, renal function recovery, dependence on renal replacement therapy, and complications such as infections or anticoagulation issues. The primary outcome measured is in-hospital mortality, with secondary outcomes covering ICU mortality, 90-day mortality, length of stay, recovery, and procedural complications. This study spans from enrollment until 90 days after ICU admission, providing extensive observational data on AKI-RRT in Latin America.
Actively Recruiting
Researchers are evaluating the potential benefits and risks of using adjunctive hydrocortisone in children with septic shock that does not respond to fluids and vasoactive medications. The trial aims to determine whether hydrocortisone can reduce the occurrence of new or worsening organ dysfunction and improve outcomes such as survival and quality of life in pediatric patients. This study is a randomized, double-blinded, placebo-controlled trial involving critically ill children in pediatric intensive care units. Participants are randomly assigned to one of two groups one receives hydrocortisone sodium succinate according to a specific dosing schedule, and the other receives a placebo of normal saline with the same volume and schedule. The hydrocortisone treatment starts with a 2 mgkg intravenous bolus followed by 1 mgkg doses every six hours for up to seven days or until vasoactive medications have been stopped for at least 12 hours. The placebo group receives an identical schedule of saline infusions. During the study, children will be monitored closely while in the intensive care unit for adverse events such as high blood sugar, gastrointestinal bleeding, delirium, and hospital-acquired infections. Researchers will assess organ dysfunction using the Pediatric Logistic Organ Dysfunction PELOD-2 tool and evaluate health-related quality of life with the Pediatric Quality of Life Inventory PedsQL at 28 days after enrollment. Follow-up assessments will also occur at 90 days. The study plans to enroll up to 500 children from multiple countries, with the goal of improving treatment guidelines for septic shock in children.
Actively Recruiting
Researchers are conducting a prospective, observational multicenter study to understand severe and very severe COPD in Brazil. This study focuses on patients diagnosed by the GOLD 2024 criteria, considering that COPD severity is linked to exacerbation rates, disease progression, complications, and mortality. It aims to gather data from multiple regions of Brazil, each with different environmental exposures and population characteristics, to fill the gap in national information about this subgroup. Participants will be enrolled consecutively across eight hospitals representing Brazils five regions. The study involves no experimental treatment instead, it observes patients over 12 months with on-site visits at the start, 6 months, and 12 months, plus tele-consultations at 3 and 9 months. Data collected will focus on exacerbations, hospitalizations, mortality, and vaccination status, among other clinical details. Participants will undergo clinical assessments during visits and tele-consults, with data managed and reviewed by the study team. Researchers will measure outcomes such as hospitalizations, exacerbations, mortality, vaccination rates, and lung cancer incidence over approximately one year. The study is observational, so patient care continues as usual, and participant involvement lasts about 12 months.